术中组织间植入(125)~I放射性粒子治疗Ⅲ b期非小细胞肺癌的临床研究  

Intraoperative ^(125)I brachytherapy for NSCLC in Ⅲ b stage.

作　　者：黄淼龙[1] 陈翀[1] 罗德源[1] 姜月平[1] 夏旭辉[1] 

机构地区：[1]韶关市粤北人民医院心胸外科,广东韶关512025

出　　处：《临床和实验医学杂志》2007年第5期41-42,共2页Journal of Clinical and Experimental Medicine

摘　　要：目的探讨术中组织间植入125I放射性粒子治疗Ⅲb期非小细胞肺癌的疗效和可行性。方法对32例Ⅲb期肺癌患者行根治手术+术中植入125I及术后化疗。术中在瘤床及淋巴引流区,每隔1 cm植入125I 1粒,术后行TP方案化疗;设同期对照30例根治性手术+术后外照射放疗及化疗,比较两组的1、3年生存率和局控率,统计采用χ2检验。结果照射组及对照组随访超过36个月。125I组1、3年生存率分别为:63.8%,31.9%,对照组1、3年生存率分别为:50.6%,26.9%,两组生存率比较差异无显著性意义(P>0.05)。两组局控率比较,125I组高于对照组(P<0.05)。结论术中植入125可减少局部复发,对总的生存改善不明显,对Ⅲb期患者有望获得治疗益处。肺癌术中植入125I可作为综合治疗方法之一,以提高疗效。Objective To evaluate the effectiveness and feasibility of intraoperative 125 Ⅰ brachytherapy for non - small cell lung cancer （NSCLC） in Ⅲ b stage. Methods 32 patients with NSCLC （ Ⅰ b stage） were treated with radical resection and permanent implanation of 125Ⅰ seeds. Contral group （ n = 30） was treated with radical resection and routine postoperative radiotherapy, The local recurrent rate, 1 - year and 3 - years survival rate between two groups were compared. The data were analyzed with X^2 test. Results Follow - up period of the two groups was over 3 years, 1 -year and 3 -years survival rate were 63.8 % and31.9 %, respectively in 125 Ⅰ group; 50,6 % and 26.9 %, respectively in control group, but the differences were notsignificant（ P 〉0.05）. Local recurrent rate of 125Ⅰ group was significantly lower than that of control group （P 〈 0.05 ）. Condusion Intraoperative 125Ⅰ brachytherapy is of benefit to NSCLC （Ⅲb stage）, it can decrease local recurrent ratel, but can not improve total survival rate. Intraoperative 125Ⅰ brachytherapy may be used in conbination treatment for NSCLC（ Ⅲb stage）, to improve therapeutic results.

关 键 词：手术植入 125ⅠⅢb期肺癌 

分 类 号：R734.2[医药卫生—肿瘤]